Cellectar amends CEO/COO severance, reduces stockholder quorum to one-third

Cellectar Biosciences, Inc.

Board on March 12, 2025 approved enhanced severance for CEO and COO upon qualifying termination after a change in control.
CEO James V. Caruso gets 24 months base salary, target bonus, and benefit continuation.
COO Jarrod Longcor gets 18 months base salary and benefit continuation.
On March 11, 2025, Board adopted amended Bylaws reducing stockholder quorum from a majority to one-third of shares.
Bylaws also revise procedural requirements for stockholder nominations and other business, and align with Delaware law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cellectar Biosciences, Inc.: Amended and restated by-laws to align with Delaware law, revise director nomination procedures, and change quorum requirement from majority to one-third of shares (effective 2025-03-11).

Change: bylaw amendment
Effective: 2025-03-11

Exact text from the filing

On March 11, 2025, the Board adopted the Amended and Restated By-Laws of the Company (the " By-Laws "), effective immediately.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-024446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.